




Belgian Cancer Registry

## CANCER FACT SHEET 2022

### MELANOMA

ICD-10 C43



## CONCEPTS AND ABBREVIATIONS

**Absolute numbers (N):** The number of newly registered cancer diagnoses observed for a given period of time. All figures and numbers in this cancer fact sheet are based on diagnoses of Belgian residents.

**Average Annual Percentage Change (AAPC):** The average relative change in incidence risk from one year to the next. For example an AAPC of 1.05 (a 5% increase) applied to a cancer risk of 200/100,000 results in a risk of 210/100,000 one year later ( $=200 \times 1.05$ ) and 255/100,000 over 5 years ( $=200 \times (1.05)^5$ ).


**Crude Rate (CR):** The crude rate is obtained by dividing the absolute number of diagnoses (N) by the corresponding population size at risk (N/100,000).

**ESR2013:** Incidence rates standardised to the 2013 revised European Standard Population (ESP): Standardisation is necessary to accommodate for differences in population size and age distribution (over time or among regions). An important factor in interpreting trends in cancer incidence is population ageing, as cancer is an age-dependent disease. For a higher proportion of elderly people in the population, a higher total number of cancer diagnoses can be expected for the same cancer risk. When only absolute numbers (N) or Crude Rate (CR) results are used, a misleading picture of the actual changes in the risk of a cancer diagnosis could be obtained. Therefore, direct standardisation is necessary to evaluate the evolution of the risk of cancer diagnosis over time or among regions.

**Net survival:** Often also called the relative survival, is an estimate of the survival probability when other causes of death beside the cancer type(s) under study are excluded. As examples of other causes of death, patients with the cancer type(s) under study could also die because of an accident or unrelated cardiac conditions, etc. Net survival may exceed 100%, this occurs when the observed survival probability for patients with the cancer type(s) under study is higher than the one for the matched general population (no excess mortality due to cancer).

**Stage:** Cancers are reported with a stage, labelled with a Roman numeral with IV being the most advanced stage. Stage is based on the T-category (extent of the tumour), the N-category (absence or presence and extent of the regional lymph node metastasis) and the M-category (absence or presence of distant metastasis). Stage is reported as clinical and pathological stage and as a combination of both clinical and pathological stage with priority given to the pathological stage. Clinical information about distant metastases (cM) will always be taken into account, and in case of neo-adjuvant therapy, priority is given to the clinical stage. If stage is unknown, not applicable or not submitted to the Belgian Cancer Registry, the stage is reported as 'unregistered stage'. Stage is reported according to the TNM 8<sup>th</sup> edition: J.D. Brierley, M.K. Gospodarowicz, Ch. Wittekind. TNM Classification of Malignant Tumours, 8th edition: UICC, 2017.

**95% CI:** 95% Confidence Intervals are indicated with a shaded band or whiskers in the figures. The 95% CI is a range of values that has 95% chance to contain the true mean value.



1. CANCER INCIDENCE .....	5
1.1. Melanoma incidence: by region.....	5
1.1.1. Melanoma incidence by region and sex: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2022.....	5
1.2. Melanoma incidence: by tumour stage .....	7
1.2.1. Melanoma incidence by clinical stage (cStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022 .....	7
1.2.2. Melanoma incidence by pathological stage (pStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022 .....	7
1.2.3. Melanoma incidence by stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022.....	8
1.2.4. Melanoma incidence by sub-location, stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022 .....	9
1.2.5. Melanoma incidence by pT sub-categories, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022 .....	11
2. CANCER INCIDENCE TRENDS .....	12
2.1. Melanoma incidence trends: by region .....	12
2.1.1. Melanoma incidence trends in males, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022 .....	12
2.1.2. Melanoma incidence trends in females, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022 .....	14
2.2. Melanoma incidence trends: by tumour stage .....	15
2.2.1. Melanoma incidence trends by stage and sex: number of new diagnoses, crude and age-standardised incidence rates, 2018-2022, including average annual percentage change from 2004 onwards .....	15
2.3. Melanoma incidence trends: by age group .....	17
2.3.1. Melanoma incidence trends in males, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022.....	17
2.3.2. Melanoma incidence trends in females, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022.....	18
3. CANCER PREVALENCE .....	19
3.1. Melanoma prevalence: by region .....	19
3.1.1. Melanoma prevalence by region and sex: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2022.....	19
4. CANCER SURVIVAL.....	20
4.1. Melanoma survival: by region.....	20
4.1.1. Melanoma survival by region, sex and age group: number at risk and net survival probabilities, 2013-2022 .....	20
4.2. Melanoma survival: by tumour stage.....	22
4.2.1. Melanoma survival by clinical stage (cStage) and sex: number at risk and net survival probabilities, 2013-2022 .....	22
4.2.2. Melanoma survival by pathological stage (pStage) and sex: number at risk and net survival probabilities, 2013-2022.....	23

4.2.3. Melanoma survival by stage and sex: number at risk and net survival probabilities, 2013-2022 .....	24
5. CANCER SURVIVAL TRENDS.....	25
5.1. Melanoma survival trends: by tumour stage .....	25
5.1.1. Melanoma survival trends by stage and sex: number at risk and net survival probabilities, 2008-2022.....	25
6. CANCER MORTALITY .....	27
6.1. Melanoma mortality: by region .....	27
6.1.1. Melanoma mortality* by region and sex: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2021 .....	27
7. CANCER MORTALITY TRENDS.....	29
7.1. Melanoma mortality trends: by region.....	29
7.1.1. Melanoma mortality* trends in males, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021 .....	29
7.1.2. Melanoma mortality* trends in females, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021 .....	31



# 1. CANCER INCIDENCE



## 1.1. Melanoma incidence: by region

1.1.1. *Melanoma incidence by region and sex: number of new diagnoses, age-specific, crude and age-standardised incidence rates, 2022*

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-		All ages
Males																						
<b>Belgium</b>	0	0	3	3	11	22	30	48	71	107	156	195	209	253	236	240	147	111	45	3	1,890	35.0
	[0.0]	[0.0]	[0.9]	[0.9]	[3.2]	[6.0]	[7.8]	[12.9]	[18.7]	[28.5]	[39.4]	[48.3]	[56.6]	[81.0]	[89.4]	[126.2]	[116.1]	[141.5]	[149.9]	[51.3]	[33.1]	(33.4; 36.5)
Brussels	0	0	0	0	0	1	1	6	7	6	11	12	12	19	18	16	17	8	3	0	137	34.3
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.0]	[1.9]	[12.9]	[15.1]	[13.8]	[27.2]	[34.6]	[42.9]	[89.7]	[109.0]	[131.4]	[210.5]	[157.3]	[138.4]	[0.0]	[22.8]	(28.3; 40.2)
Flanders	0	0	3	2	11	17	23	33	35	73	116	136	132	163	160	159	100	80	32	3	1,278	38.5
	[0.0]	[0.0]	[1.5]	[1.1]	[5.8]	[8.4]	[10.9]	[15.7]	[16.0]	[34.6]	[50.2]	[55.7]	[58.7]	[84.9]	[99.0]	[128.8]	[119.7]	[152.5]	[160.6]	[79.4]	[38.5]	(36.4; 40.6)
Wallonia	0	0	0	1	0	4	6	9	29	28	29	47	65	71	58	65	30	23	10	0	475	28.8
	[0.0]	[0.0]	[0.0]	[0.9]	[0.0]	[3.6]	[5.0]	[7.8]	[25.0]	[23.2]	[23.3]	[37.6]	[56.0]	[71.5]	[67.6]	[119.0]	[85.8]	[110.1]	[126.1]	[0.0]	[26.5]	(26.2; 31.5)
Females																						
<b>Belgium</b>	0	0	0	5	19	41	80	100	153	172	244	246	251	230	231	201	128	99	43	13	2,256	37.6
	[0.0]	[0.0]	[0.0]	[1.6]	[5.7]	[11.4]	[20.9]	[26.8]	[40.4]	[46.8]	[63.1]	[61.7]	[66.6]	[69.2]	[78.2]	[87.0]	[71.8]	[73.5]	[62.0]	[63.4]	[38.4]	(36.0; 39.2)
Brussels	0	0	0	1	0	4	6	2	9	9	10	7	19	6	20	12	5	5	6	2	123	23.2
	[0.0]	[0.0]	[0.0]	[2.9]	[0.0]	[7.4]	[11.3]	[4.2]	[20.0]	[22.4]	[26.8]	[20.7]	[63.9]	[24.1]	[93.8]	[69.6]	[38.4]	[49.7]	[103.9]	[97.0]	[19.8]	(19.0; 27.4)

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-		All ages
Flanders	0	0	0	4	15	26	55	65	108	117	177	178	178	165	152	139	96	65	34	5	1,579	44.7
	[0.0]	[0.0]	[0.0]	[2.3]	[8.3]	[13.1]	[26.0]	[31.0]	[49.8]	[56.6]	[78.6]	[74.7]	[79.3]	[83.4]	[87.5]	[97.2]	[85.7]	[76.4]	[79.8]	[41.4]	[46.7]	(42.5; 46.9)
Wallonia	0	0	0	0	4	11	19	33	36	46	57	61	54	59	59	50	27	29	3	6	554	29.1
	[0.0]	[0.0]	[0.0]	[0.0]	[3.7]	[10.2]	[16.0]	[28.5]	[31.0]	[38.3]	[45.8]	[48.1]	[44.1]	[53.7]	[58.8]	[70.5]	[50.8]	[73.4]	[14.3]	[94.1]	[29.6]	(26.6; 31.5)

## 1.2. Melanoma incidence: by tumour stage

1.2.1. Melanoma incidence by clinical stage (cStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

cStage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-49	50-64	65+	All ages		15-49	50-64	65+	All ages	
I	240 [9.4]	463 [39.6]	703 [69.8]	1,409 [24.7]	25.7 (24.4; 27.1)	514 [20.5]	627 [53.9]	645 [51.1]	1,786 [30.4]	30.2 (28.8; 31.6)
II	35 [1.4]	72 [6.2]	242 [24.0]	349 [6.1]	6.7 (6.0; 7.5)	39 [1.6]	80 [6.9]	218 [17.3]	337 [5.7]	5.3 (4.7; 5.9)
III	6 [0.2]	5 [0.4]	20 [2.0]	31 [0.5]	0.6 (0.4; 0.8)	8 [0.3]	8 [0.7]	22 [1.7]	38 [0.6]	0.6 (0.4; 0.8)
IV	2 [0.1]	5 [0.4]	24 [2.4]	31 [0.5]	0.6 (0.4; 0.8)	1 [0.0]	5 [0.4]	17 [1.3]	23 [0.4]	0.3 (0.2; 0.5)
X/NA	9 [0.4]	15 [1.3]	46 [4.6]	70 [1.2]	1.3 (1.0; 1.6)	8 [0.3]	21 [1.8]	43 [3.4]	72 [1.2]	1.1 (0.9; 1.4)

1.2.2. Melanoma incidence by pathological stage (pStage), sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

pStage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-49	50-64	65+	All ages		15-49	50-64	65+	All ages	
I	234 [9.2]	450 [38.5]	691 [68.6]	1,378 [24.1]	25.2 (23.8; 26.5)	506 [20.2]	618 [53.2]	641 [50.8]	1,765 [30.0]	29.8 (28.4; 31.2)
II	34 [1.3]	53 [4.5]	217 [21.5]	304 [5.3]	5.9 (5.2; 6.6)	29 [1.2]	60 [5.2]	199 [15.8]	288 [4.9]	4.5 (4.0; 5.0)
III	13 [0.5]	39 [3.3]	64 [6.4]	116 [2.0]	2.1 (1.7; 2.5)	25 [1.0]	36 [3.1]	52 [4.1]	113 [1.9]	1.9 (1.5; 2.2)
IV	0 [0.0]	2 [0.2]	9 [0.9]	11 [0.2]	0.2 (0.1; 0.3)	1 [0.0]	4 [0.3]	6 [0.5]	11 [0.2]	0.2 (0.1; 0.3)
X/NA	11 [0.4]	16 [1.4]	54 [5.4]	81 [1.4]	1.5 (1.2; 1.9)	9 [0.4]	23 [2.0]	47 [3.7]	79 [1.3]	1.2 (1.0; 1.5)

1.2.3. Melanoma incidence by stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

Stage	Males					Females				
	N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
	15-49	50-64	65+	All ages		15-49	50-64	65+	All ages	
<b>I</b>	234 [9.2]	450 [38.5]	689 [68.4]	1,376 [24.1]	25.1 (23.8; 26.5)	506 [20.2]	618 [53.2]	639 [50.6]	1,763 [30.0]	29.8 (28.4; 31.2)
<b>II</b>	33 [1.3]	51 [4.4]	209 [20.7]	293 [5.1]	5.7 (5.0; 6.4)	29 [1.2]	59 [5.1]	192 [15.2]	280 [4.8]	4.4 (3.8; 4.9)
<b>III</b>	14 [0.5]	38 [3.2]	62 [6.2]	114 [2.0]	2.1 (1.7; 2.5)	26 [1.0]	38 [3.3]	54 [4.3]	118 [2.0]	1.9 (1.6; 2.3)
<b>IV</b>	2 [0.1]	6 [0.5]	29 [2.9]	37 [0.6]	0.7 (0.5; 0.9)	1 [0.0]	6 [0.5]	19 [1.5]	26 [0.4]	0.4 (0.2; 0.5)
<b>X/NA</b>	9 [0.4]	15 [1.3]	46 [4.6]	70 [1.2]	1.3 (1.0; 1.6)	8 [0.3]	20 [1.7]	41 [3.2]	69 [1.2]	1.1 (0.8; 1.4)



1.2.4. Melanoma incidence by sub-location, stage, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

Sub-locations	Stage	Males					Females				
		N[CR]		ESR2013 (95%CI)			N[CR]		ESR2013 (95%CI)		
		15-49	50-64	65+	All ages			15-49	50-64	65+	All ages
Head	All	30 [1.2]	63 [5.4]	239 [23.7]	333 [5.8]	6.4 (5.7; 7.1)	38 [1.5]	49 [4.2]	159 [12.6]	246 [4.2]	3.8 (3.4; 4.3)
	I	23 [0.9]	50 [4.3]	144 [14.3]	218 [3.8]	4.1 (3.6; 4.7)	36 [1.4]	42 [3.6]	108 [8.6]	186 [3.2]	3.0 (2.6; 3.4)
	II	7 [0.3]	9 [0.8]	78 [7.7]	94 [1.6]	1.9 (1.5; 2.3)	2 [0.1]	5 [0.4]	42 [3.3]	49 [0.8]	0.7 (0.5; 0.9)
	III	0 [0.0]	3 [0.3]	7 [0.7]	10 [0.2]	0.2 (0.1; 0.3)	0 [0.0]	1 [0.1]	5 [0.4]	6 [0.1]	0.1 (0.0; 0.2)
	IV	0 [0.0]	1 [0.1]	6 [0.6]	7 [0.1]	0.1 (0.0; 0.3)	0 [0.0]	0 [0.0]	1 [0.1]	1 [0.0]	0.0 (0.0; 0.0)
	X/NA	0 [0.0]	0 [0.0]	4 [0.4]	4 [0.1]	0.1 (0.0; 0.1)	0 [0.0]	1 [0.1]	3 [0.2]	4 [0.1]	0.1 (0.0; 0.1)
Trunk	All	139 [5.5]	279 [23.9]	396 [39.3]	814 [14.3]	14.8 (13.8; 15.9)	175 [7.0]	224 [19.3]	182 [14.4]	581 [9.9]	9.9 (9.1; 10.7)
	I	120 [4.7]	236 [20.2]	302 [30.0]	658 [11.5]	11.9 (11.0; 12.8)	153 [6.1]	190 [16.3]	143 [11.3]	486 [8.3]	8.3 (7.6; 9.1)
	II	11 [0.4]	22 [1.9]	61 [6.1]	94 [1.6]	1.8 (1.4; 2.1)	6 [0.2]	17 [1.5]	22 [1.7]	45 [0.8]	0.8 (0.5; 1.0)
	III	6 [0.2]	16 [1.4]	23 [2.3]	45 [0.8]	0.8 (0.6; 1.1)	14 [0.6]	13 [1.1]	8 [0.6]	35 [0.6]	0.6 (0.4; 0.8)
	IV	0 [0.0]	1 [0.1]	9 [0.9]	10 [0.2]	0.2 (0.1; 0.3)	1 [0.0]	3 [0.3]	5 [0.4]	9 [0.2]	0.1 (0.0; 0.2)
	X/NA	2 [0.1]	4 [0.3]	1 [0.1]	7 [0.1]	0.1 (0.0; 0.2)	1 [0.0]	1 [0.1]	4 [0.3]	6 [0.1]	0.1 (0.0; 0.2)
Upper limb	All	51 [2.0]	117 [10.0]	233 [23.1]	402 [7.0]	7.4 (6.7; 8.2)	134 [5.3]	170 [14.6]	267 [21.2]	571 [9.7]	9.5 (8.7; 10.3)
	I	42 [1.6]	95 [8.1]	165 [16.4]	303 [5.3]	5.5 (4.9; 6.2)	125 [5.0]	146 [12.6]	192 [15.2]	463 [7.9]	7.8 (7.1; 8.5)
	II	5 [0.2]	7 [0.6]	44 [4.4]	56 [1.0]	1.1 (0.8; 1.4)	9 [0.4]	13 [1.1]	54 [4.3]	76 [1.3]	1.2 (0.9; 1.5)
	III	3 [0.1]	12 [1.0]	15 [1.5]	30 [0.5]	0.5 (0.4; 0.7)	0 [0.0]	10 [0.9]	15 [1.2]	25 [0.4]	0.4 (0.2; 0.6)
	IV	1 [0.0]	3 [0.3]	8 [0.8]	12 [0.2]	0.2 (0.1; 0.4)	0 [0.0]	1 [0.1]	3 [0.2]	4 [0.1]	0.1 (0.0; 0.1)
	X/NA	0 [0.0]	0 [0.0]	1 [0.1]	1 [0.0]	0.0 (0.0; 0.1)	0 [0.0]	0 [0.0]	3 [0.2]	3 [0.1]	0.0 (0.0; 0.1)
Lower limb	All	63 [2.5]	88 [7.5]	123 [12.2]	275 [4.8]	5.0 (4.4; 5.6)	217 [8.6]	281 [24.2]	304 [24.1]	802 [13.7]	13.4 (12.5; 14.4)
	I	48 [1.9]	68 [5.8]	75 [7.4]	192 [3.4]	3.5 (3.0; 3.9)	192 [7.6]	240 [20.6]	193 [15.3]	625 [10.6]	10.6 (9.8; 11.5)
	II	10 [0.4]	13 [1.1]	26 [2.6]	49 [0.9]	0.9 (0.7; 1.2)	11 [0.4]	24 [2.1]	74 [5.9]	109 [1.9]	1.7 (1.4; 2.0)

Sub-locations	Stage	Males					Females				
		N[CR]				ESR2013 (95%CI)	N[CR]				ESR2013 (95%CI)
		15-49	50-64	65+	All ages		15-49	50-64	65+	All ages	
	<b>III</b>	4 [0.2]	7 [0.6]	17 [1.7]	28 [0.5]	0.5 (0.3; 0.7)	12 [0.5]	14 [1.2]	26 [2.1]	52 [0.9]	0.8 (0.6; 1.1)
	<b>IV</b>	0 [0.0]	0 [0.0]	4 [0.4]	4 [0.1]	0.1 (0.0; 0.1)	0 [0.0]	2 [0.2]	10 [0.8]	12 [0.2]	0.2 (0.1; 0.3)
	<b>X/NA</b>	1 [0.0]	0 [0.0]	1 [0.1]	2 [0.0]	0.0 (0.0; 0.1)	2 [0.1]	1 [0.1]	1 [0.1]	4 [0.1]	0.1 (0.0; 0.1)
<b>Overlapping sites or unspecified</b>	<b>All</b>	9 [0.4]	13 [1.1]	44 [4.4]	66 [1.2]	1.3 (1.0; 1.6)	6 [0.2]	17 [1.5]	33 [2.6]	56 [1.0]	0.9 (0.7; 1.1)
	<b>I</b>	1 [0.0]	1 [0.1]	3 [0.3]	5 [0.1]	0.1 (0.0; 0.2)	0 [0.0]	0 [0.0]	3 [0.2]	3 [0.1]	0.1 (0.0; 0.1)
	<b>II</b>	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)	1 [0.0]	0 [0.0]	0 [0.0]	1 [0.0]	0.0 (0.0; 0.1)
	<b>III</b>	1 [0.0]	0 [0.0]	0 [0.0]	1 [0.0]	0.0 (0.0; 0.1)	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
	<b>IV</b>	1 [0.0]	1 [0.1]	2 [0.2]	4 [0.1]	0.1 (0.0; 0.1)	0 [0.0]	0 [0.0]	0 [0.0]	0 [0.0]	0.0 (0.0; 0.0)
	<b>X/NA</b>	6 [0.2]	11 [0.9]	39 [3.9]	56 [1.0]	1.1 (0.8; 1.4)	5 [0.2]	17 [1.5]	30 [2.4]	52 [0.9]	0.8 (0.6; 1.1)

1.2.5. Melanoma incidence by pT sub-categories, sex and age group: number of new diagnoses, crude and age-standardised incidence rates, 2022

pT	Males					Females				
	N[CR]		ESR2013 (95%CI)			N[CR]		ESR2013 (95%CI)		
	15-49	50-64	65+	All ages	15-49	50-64	65+	All ages		
<b>1</b>	200 [7.9]	385 [32.9]	573 [56.9]	1,159 [20.3]	21.2 (19.9; 22.4)	448 [17.8]	535 [46.0]	530 [42.0]	1,513 [25.8]	25.7 (24.4; 27.0)
1a	168 [6.6]	324 [27.7]	498 [49.4]	991 [17.4]	18.1 (17.0; 19.2)	378 [15.1]	466 [40.1]	440 [34.9]	1,284 [21.9]	21.8 (20.6; 23.0)
1b	32 [1.3]	58 [5.0]	71 [7.0]	161 [2.8]	2.9 (2.5; 3.4)	68 [2.7]	67 [5.8]	86 [6.8]	221 [3.8]	3.7 (3.2; 4.2)
<b>2</b>	46 [1.8]	84 [7.2]	150 [14.9]	282 [4.9]	5.2 (4.6; 5.8)	81 [3.2]	103 [8.9]	145 [11.5]	329 [5.6]	5.5 (4.9; 6.1)
2a	41 [1.6]	77 [6.6]	132 [13.1]	252 [4.4]	4.6 (4.0; 5.2)	70 [2.8]	93 [8.0]	121 [9.6]	284 [4.8]	4.7 (4.2; 5.3)
2b	5 [0.2]	6 [0.5]	16 [1.6]	27 [0.5]	0.5 (0.3; 0.7)	11 [0.4]	10 [0.9]	22 [1.7]	43 [0.7]	0.7 (0.5; 0.9)
<b>3</b>	28 [1.1]	40 [3.4]	115 [11.4]	183 [3.2]	3.5 (3.0; 4.0)	14 [0.6]	47 [4.0]	112 [8.9]	173 [2.9]	2.7 (2.3; 3.1)
3a	16 [0.6]	26 [2.2]	62 [6.2]	104 [1.8]	2.0 (1.6; 2.3)	12 [0.5]	21 [1.8]	58 [4.6]	91 [1.5]	1.4 (1.1; 1.7)
3b	12 [0.5]	13 [1.1]	52 [5.2]	77 [1.3]	1.5 (1.1; 1.8)	2 [0.1]	24 [2.1]	53 [4.2]	79 [1.3]	1.2 (1.0; 1.5)
<b>4</b>	7 [0.3]	35 [3.0]	141 [14.0]	183 [3.2]	3.6 (3.1; 4.1)	17 [0.7]	30 [2.6]	108 [8.6]	155 [2.6]	2.4 (2.0; 2.8)
4a	4 [0.2]	12 [1.0]	52 [5.2]	68 [1.2]	1.3 (1.0; 1.6)	7 [0.3]	14 [1.2]	32 [2.5]	53 [0.9]	0.8 (0.6; 1.1)
4b	3 [0.1]	22 [1.9]	88 [8.7]	113 [2.0]	2.2 (1.8; 2.7)	10 [0.4]	15 [1.3]	73 [5.8]	98 [1.7]	1.5 (1.2; 1.8)
<b>X/NA</b>	11 [0.4]	16 [1.4]	56 [5.6]	83 [1.5]	1.6 (1.2; 1.9)	10 [0.4]	26 [2.2]	50 [4.0]	86 [1.5]	1.3 (1.1; 1.6)

## 2. CANCER INCIDENCE TRENDS



### 2.1. Melanoma incidence trends: by region

2.1.1. *Melanoma incidence trends in males, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022*

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	
Belgium	<b>N</b>	634	633	626	733	753	730	888	946	1,091	1,099	1,199	1,204	1,283	1,467	1,552	1,663	1,660	1,709	1,890			
	<b>CR</b>	12.5	12.4	12.2	14.1	14.4	13.9	16.7	17.6	20.2	20.2	21.9	21.9	23.2	26.3	27.7	29.5	29.3	30.1	33.1			
	<b>ESR2013</b>	14.2	14.3	13.9	15.7	16.4	15.7	18.6	19.9	22.2	22.3	24.1	24.1	25.2	28.3	29.8	31.5	31.1	31.7	35.0	5.5 (5.1; 6.0)	2004-2022	
																					5.9 (5.2; 6.7)	2004-2016	
																						4.7 (3.1; 6.3)	2017-2022
Brussels	<b>N</b>	58	62	57	70	72	79	84	100	92	96	105	83	100	96	114	92	99	99	137			
	<b>CR</b>	12.1	12.8	11.6	14.1	14.2	15.3	15.9	18.4	16.6	17.1	18.5	14.5	17.2	16.5	19.4	15.5	16.6	16.5	22.8			
	<b>ESR2013</b>	15.1	17.1	15.9	17.7	19.4	20.3	20.8	25.4	23.6	24.3	25.8	22.0	26.0	24.7	28.5	22.9	26.6	24.6	34.3	3.6 (2.7; 4.5)	2004-2022	
																					6.8 (3.8; 9.9)	2004-2010	
																						2.1 (0.7; 3.4)	2011-2022
Flanders	<b>N</b>	374	379	387	442	425	407	478	529	634	680	726	725	773	886	983	1,084	1,106	1,166	1,278			
	<b>CR</b>	12.6	12.7	12.9	14.7	14.0	13.3	15.5	17.0	20.2	21.6	22.9	22.8	24.1	27.5	30.3	33.3	33.7	35.4	38.5			
	<b>ESR2013</b>	13.9	13.8	13.9	15.8	15.4	14.4	16.8	18.2	21.3	22.8	24.0	23.5	24.9	28.1	30.8	33.6	33.9	35.4	38.5	6.2 (5.7; 6.8)	2004-2022	
																					4.2 (2.4; 6.0)	2004-2010	
																						7.2 (6.4; 8.1)	2011-2022

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period
Wallonia <b>N</b>	202	192	182	221	256	244	326	317	365	323	368	396	410	485	455	487	455	444	475		
<b>CR</b>	12.3	11.7	11.0	13.3	15.3	14.5	19.2	18.5	21.2	18.6	21.1	22.6	23.3	27.5	25.7	27.4	25.5	24.9	26.5		
<b>ESR2013</b>	14.3	14.7	13.4	15.0	18.1	17.2	21.8	21.9	23.8	20.9	24.2	26.1	25.9	30.1	28.5	29.9	27.5	26.7	28.8	4.4 (3.6; 5.1)	2004-2022
																				6.5 (5.3; 7.8)	2004-2015
																				1.1 (-0.9; 3.1)	2016-2022

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.1.2. Melanoma incidence trends in females, by region: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period			
Belgium	<b>N</b>	885	967	977	982	1,158	1,192	1,252	1,261	1,408	1,561	1,734	1,640	1,789	1,929	1,965	2,087	1,970	2,277	2,256				
	<b>CR</b>	16.7	18.1	18.2	18.2	21.3	21.7	22.6	22.6	25.0	27.6	30.5	28.8	31.2	33.5	34.0	36.0	33.8	39.0	38.4				
	<b>ESR2013</b>	16.8	18.4	18.4	18.2	21.3	21.6	22.7	22.5	25.1	27.9	30.5	28.8	31.0	33.3	33.9	35.7	33.3	38.2	37.6	4.6 (4.2; 5.1)	2004-2022		
																						5.4 (4.8; 6.0)	2004-2017	
																							2.6 (0.9; 4.3)	2018-2022
Brussels	<b>N</b>	81	82	88	95	97	112	105	110	112	104	113	98	139	117	125	119	114	139	123				
	<b>CR</b>	15.6	15.7	16.6	17.8	17.9	20.3	18.7	19.1	19.1	17.5	18.9	16.3	22.9	19.2	20.4	19.3	18.4	22.4	19.8				
	<b>ESR2013</b>	16.9	16.9	18.6	19.4	18.4	21.8	21.1	20.2	22.4	19.5	21.3	18.9	26.1	21.7	24.4	22.9	21.7	25.5	23.2	1.8 (1.1; 2.5)	2004-2022		
Flanders	<b>N</b>	497	558	602	579	686	720	688	697	853	997	1,059	1,044	1,086	1,217	1,289	1,416	1,314	1,560	1,579				
	<b>CR</b>	16.3	18.2	19.5	18.7	22.0	22.9	21.7	21.8	26.5	30.9	32.6	32.0	33.1	36.9	38.9	42.5	39.2	46.4	46.7				
	<b>ESR2013</b>	16.2	18.2	19.4	18.4	21.6	22.5	21.3	21.4	26.0	30.6	32.0	31.3	32.2	36.0	37.8	41.3	37.8	44.7	44.7	5.9 (5.3; 6.5)	2004-2022		
Wallonia	<b>N</b>	307	327	287	308	375	360	459	454	443	460	562	498	564	595	551	552	542	578	554				
	<b>CR</b>	17.6	18.7	16.3	17.4	21.1	20.1	25.5	25.1	24.3	25.2	30.6	27.1	30.6	32.2	29.7	29.7	29.1	31.0	29.6				
	<b>ESR2013</b>	18.2	19.2	16.6	17.7	21.5	20.3	25.9	25.2	24.7	25.4	30.7	27.4	30.7	32.3	29.9	29.8	28.8	30.5	29.1	3.1 (2.4; 3.7)	2004-2022		
																						5.1 (4.1; 6.2)	2004-2016	
																							-0.9 (-3.1; 1.3)	2017-2022

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

## 2.2. Melanoma incidence trends: by tumour stage

2.2.1. Melanoma incidence trends by stage and sex: number of new diagnoses, crude and age-standardised incidence rates, 2018-2022, including average annual percentage change from 2004 onwards

Stage	Males							Females							
	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	
<b>I</b>	<b>N</b>	1,116	1,187	1,196	1,252	1,376			1,545	1,637	1,562	1,800	1,763		
	<b>CR</b>	19.9	21.1	21.1	22.1	24.1			26.7	28.2	26.8	30.8	30.0		
	<b>ESR2013</b>	21.1	22.3	22.2	22.9	25.1	8.5 (7.7; 9.4)	2004-2022	27.0	28.4	26.8	30.8	29.8	6.9 (5.9; 8.0)	2004-2022
							9.9 (8.9; 11.0)	2004-2018						8.0 (5.9; 10.2)	2004-2013
						3.7 (-0.2; 7.9)	2019-2022						10.0 (5.4; 14.9)	2014-2017	
													2.7 (-1.6; 7.1)	2018-2022	
<b>II</b>	<b>N</b>	230	260	247	235	293			254	277	226	293	280		
	<b>CR</b>	4.1	4.6	4.4	4.1	5.1			4.4	4.8	3.9	5.0	4.8		
	<b>ESR2013</b>	4.6	5.1	4.9	4.6	5.7	4.1 (3.4; 4.9)	2004-2022	4.1	4.4	3.5	4.5	4.4	3.6 (2.5; 4.6)	2004-2022
														5.5 (3.8; 7.1)	2004-2016
													-0.1 (-3.5; 3.4)	2017-2022	
<b>III</b>	<b>N</b>	104	111	119	127	114			79	93	112	110	118		
	<b>CR</b>	1.9	2.0	2.1	2.2	2.0			1.4	1.6	1.9	1.9	2.0		
	<b>ESR2013</b>	2.0	2.1	2.2	2.4	2.1	6.1 (5.0; 7.2)	2004-2022	1.4	1.6	1.9	1.8	1.9	5.9 (4.7; 7.2)	2004-2022
<b>IV</b>	<b>N</b>	26	42	40	35	37			21	20	28	26	26		
	<b>CR</b>	0.5	0.7	0.7	0.6	0.6			0.4	0.3	0.5	0.4	0.4		
	<b>ESR2013</b>	0.5	0.8	0.8	0.7	0.7	2.2 (0.4; 4.0)	2004-2022	0.3	0.3	0.4	0.4	0.4	0.4 (-2.1; 2.9)	2004-2022
<b>X/NA</b>	<b>N</b>	76	63	58	60	70			66	60	42	48	69		
	<b>CR</b>	1.4	1.1	1.0	1.1	1.2			1.1	1.0	0.7	0.8	1.2		
	<b>ESR2013</b>	1.5	1.2	1.1	1.2	1.3	-7.7 (-10.2; -5.1)	2004-2022	1.1	1.0	0.7	0.8	1.1	-11.0 (-14.1; -7.8)	2004-2022

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.



## 2.3. Melanoma incidence trends: by age group

2.3.1. Melanoma incidence trends in males, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022

Age	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	
<b>15-49 N</b>	213	200	203	229	208	198	275	247	323	253	325	255	290	327	325	285	289	282	292			
<b>CR</b>	8.4	7.9	8.0	9.0	8.2	7.8	10.8	9.6	12.6	9.9	12.7	10.0	11.4	12.9	12.8	11.2	11.4	11.1	11.5			
<b>ESR2013</b>	8.4	7.9	8.0	9.0	8.1	7.8	10.8	9.6	12.6	9.9	12.8	10.1	11.6	13.1	13.0	11.5	11.7	11.4	11.8	2.4 (1.4; 3.3)	2004-2022	
																				3.9 (2.4; 5.4)	2004-2016	
																					-0.7 (-3.8; 2.6)	2017-2022
<b>50-64 N</b>	169	148	170	223	230	213	259	293	334	340	353	378	397	465	490	542	570	584	560			
<b>CR</b>	18.7	16.0	18.0	23.0	23.1	20.9	24.9	27.6	31.2	31.4	32.2	34.0	35.3	40.9	42.8	47.1	49.2	50.1	47.9			
<b>ESR2013</b>	18.8	16.3	18.3	23.0	23.2	21.0	25.1	27.7	31.3	31.4	32.3	34.2	35.5	41.1	42.9	47.0	49.0	49.8	47.6	6.5 (5.8; 7.1)	2004-2022	
<b>65+ N</b>	249	284	250	278	314	317	353	405	432	506	521	571	596	673	736	835	800	842	1,035			
<b>CR</b>	33.8	38.1	33.2	36.9	41.3	41.1	45.0	50.8	52.7	60.4	60.8	65.1	66.5	73.6	78.9	87.7	82.2	85.3	102.7			
<b>ESR2013</b>	34.2	38.6	34.0	36.5	42.2	41.4	45.3	51.9	53.5	60.4	61.8	65.7	67.0	73.7	79.6	87.8	83.5	86.3	104.1	6.4 (5.9; 6.9)	2004-2022	

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

2.3.2. Melanoma incidence trends in females, by age group: number of new diagnoses, crude and age-standardised incidence rates, including average annual percentage change, 2004-2022

Age	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	AAPC, % (95%CI)	Period	
<b>15-49</b>																						
<b>N</b>	370	393	399	383	498	462	529	524	545	584	630	553	600	656	634	645	572	633	570			
<b>CR</b>	15.0	15.9	16.1	15.4	20.0	18.5	21.1	20.8	21.6	23.2	25.1	22.1	24.0	26.3	25.4	25.9	22.9	25.3	22.7			
<b>ESR2013</b>	14.9	15.8	16.1	15.4	20.0	18.5	21.2	21.0	21.8	23.4	25.3	22.3	24.4	26.6	25.9	26.2	23.2	25.9	23.2	2.9 (2.4; 3.5)	2004-2022	
																				5.3 (4.2; 6.5)	2004-2014	
																				0.0 (-1.4; 1.4)	2015-2022	
<b>50-64</b>																						
<b>N</b>	213	251	235	280	288	331	322	305	380	443	518	510	544	570	607	691	660	760	741			
<b>CR</b>	23.2	26.9	24.6	28.5	28.6	32.2	30.7	28.5	35.1	40.5	46.9	45.6	48.1	50.0	52.9	60.0	57.1	65.5	63.7			
<b>ESR2013</b>	23.1	27.1	24.9	28.6	28.7	32.2	30.7	28.5	35.1	40.5	47.0	45.5	48.1	50.0	53.1	60.1	57.0	65.6	63.7	6.1 (5.4; 6.8)	2004-2022	
<b>65+</b>																						
<b>N</b>	300	321	340	318	370	398	397	429	481	532	584	576	643	700	724	750	737	883	945			
<b>CR</b>	28.7	30.5	32.2	30.1	35.0	37.3	36.9	39.5	43.5	47.5	51.4	50.0	55.1	59.3	60.5	61.8	59.9	71.1	74.9			
<b>ESR2013</b>	28.6	30.3	31.8	29.4	34.3	36.0	36.5	38.5	43.3	48.4	50.7	50.6	54.6	59.1	60.9	62.3	60.1	70.6	75.5	5.6 (5.2; 6.1)	2004-2022	

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.



#### 3.1. Melanoma prevalence: by region

3.1.1. *Melanoma prevalence by region and sex: number of prevalent cases, crude and age-standardised prevalence rates on 31/12/2022*

Region		Males				Females			
		1-year	5-year	10-year	15-year	1-year	5-year	10-year	15-year
Belgium	<b>N</b>	1,791	7,319	11,629	14,031	2,177	9,644	16,541	20,800
	<b>CR</b>	31.1	127.0	201.8	244	36.7	162.5	278.6	350
	<b>ESR2013</b>	32.6	132.7	211.1	254.9	35.9	159.1	272.3	342.2
Brussels	<b>N</b>	126	446	753	959	115	560	974	1,293
	<b>CR</b>	20.7	73.3	123.8	157.7	18.2	88.5	153.9	204.3
	<b>ESR2013</b>	30.9	110.7	187.7	238.0	21.5	105.0	181.7	242.1
Flanders	<b>N</b>	1,212	4,895	7,530	8,868	1,534	6,574	10,902	13,369
	<b>CR</b>	36.2	146.0	224.6	264.5	44.8	192.1	318.5	390.6
	<b>ESR2013</b>	36.0	144.8	222.6	262.2	42.9	184.1	303.8	371.9
Wallonia	<b>N</b>	453	1,978	3,346	4,204	528	2,510	4,665	6,138
	<b>CR</b>	25.2	109.8	185.8	233.4	28.1	133.5	248.0	326.4
	<b>ESR2013</b>	27.0	116.9	198.4	249.9	27.5	131.2	243.8	320.7



### 4.1. Melanoma survival: by region

#### 4.1.1. Melanoma survival by region, sex and age group: number at risk and net survival probabilities, 2013-2022

Net Survival Probability, 2013-2022						
Region	Age	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	10-y (95%CI)
Total	All	32,869	98.3% (98.0%; 98.5%)	95.9% (95.5%; 96.3%)	95.0% (94.4%; 95.6%)	96.4% (94.0%; 98.8%)
Males						
Belgium	All ages	14,205	97.5% (97.1%; 97.9%)	94.4% (93.8%; 95.1%)	93.7% (92.7%; 94.7%)	94.1% (89.2%; 99.3%)
	15-49	2,844	99.0% (98.6%; 99.4%)	96.6% (95.9%; 97.3%)	95.3% (94.4%; 96.2%)	93.3% (91.8%; 94.8%)
	50-64	4,544	97.9% (97.4%; 98.4%)	94.4% (93.6%; 95.3%)	93.5% (92.5%; 94.6%)	93.0% (91.0%; 95.1%)
	65+	6,841	96.7% (96.0%; 97.4%)	93.6% (92.3%; 94.9%)	93.3% (91.3%; 95.3%)	95.5% (85.1%; 107.2%)
Brussels	All ages	971	97.2% (95.7%; 98.8%)	94.8% (92.1%; 97.6%)	91.2% (86.6%; 95.9%)	90.5% (79.6%; 102.8%)
	15-49	165	99.6% (98.4%; 100.8%)	93.8% (89.8%; 97.9%)	92.6% (88.1%; 97.3%)	91.0% (85.2%; 97.3%)
	50-64	278	97.1% (94.9%; 99.3%)	93.6% (90.1%; 97.2%)	92.4% (88.3%; 96.7%)	89.1% (81.3%; 97.7%)
	65+	528	96.6% (94.0%; 99.2%)	95.8% (91.2%; 100.5%)	90.0% (82.2%; 98.4%)	91.1% (72.1%; 114.9%)
Flanders	All ages	9,087	98.0% (97.5%; 98.4%)	95.4% (94.5%; 96.3%)	95.3% (94.0%; 96.6%)	97.4% (90.1%; 105.4%)
	15-49	1,714	98.9% (98.4%; 99.5%)	96.7% (95.8%; 97.7%)	95.7% (94.6%; 96.9%)	93.6% (91.6%; 95.6%)
	50-64	2,970	98.2% (97.6%; 98.8%)	95.1% (94.0%; 96.1%)	94.4% (93.2%; 95.7%)	96.0% (93.6%; 98.5%)
	65+	4,418	97.4% (96.5%; 98.3%)	95.1% (93.5%; 96.8%)	95.8% (93.4%; 98.3%)	100.3% (85.1%; 118.2%)
Wallonia	All ages	4,149	96.6% (95.9%; 97.4%)	92.3% (91.1%; 93.6%)	91.1% (89.3%; 92.8%)	88.3% (83.3%; 93.5%)

Net Survival Probability, 2013-2022						
Region	Age	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	10-y (95%CI)
	<b>15-49</b>	966	98.9% (98.2%; 99.6%)	96.8% (95.6%; 98.1%)	95.0% (93.5%; 96.6%)	93.1% (90.6%; 95.7%)
	<b>50-64</b>	1,297	97.3% (96.3%; 98.3%)	93.2% (91.5%; 94.8%)	91.7% (89.8%; 93.7%)	87.5% (83.6%; 91.6%)
	<b>65+</b>	1,895	95.0% (93.6%; 96.4%)	89.5% (87.1%; 91.9%)	88.6% (85.1%; 92.2%)	86.3% (75.4%; 98.9%)
Females						
<b>Belgium</b>	<b>All ages</b>	18,664	98.8% (98.6%; 99.1%)	97.0% (96.5%; 97.5%)	96.0% (95.3%; 96.7%)	98.0% (96.2%; 100.0%)
	<b>15-49</b>	5,934	99.7% (99.5%; 99.9%)	98.7% (98.4%; 99.0%)	98.1% (97.7%; 98.5%)	97.3% (96.6%; 98.0%)
	<b>50-64</b>	5,878	99.3% (99.0%; 99.6%)	98.2% (97.7%; 98.7%)	97.6% (96.9%; 98.2%)	96.9% (95.6%; 98.2%)
	<b>65+</b>	6,888	97.6% (97.0%; 98.3%)	94.6% (93.4%; 95.8%)	92.8% (91.0%; 94.7%)	100.4% (94.9%; 106.1%)
Brussels	<b>All ages</b>	1,150	98.2% (97.0%; 99.5%)	96.9% (94.7%; 99.1%)	96.0% (92.8%; 99.4%)	104.1% (95.9%; 113.1%)
	<b>15-49</b>	328	100.1% (100.1%; 100.1%)	98.0% (96.3%; 99.7%)	97.1% (94.9%; 99.2%)	95.8% (92.2%; 99.6%)
	<b>50-64</b>	314	99.1% (97.9%; 100.4%)	98.1% (96.1%; 100.1%)	97.4% (94.8%; 100.1%)	97.4% (92.9%; 102.1%)
	<b>65+</b>	513	96.5% (93.9%; 99.2%)	95.5% (91.0%; 100.3%)	94.6% (87.7%; 101.9%)	114.9% (95.4%; 138.4%)
Flanders	<b>All ages</b>	12,213	99.0% (98.7%; 99.3%)	97.4% (96.9%; 98.0%)	96.8% (95.9%; 97.6%)	98.5% (96.2%; 100.9%)
	<b>15-49</b>	3,665	99.7% (99.5%; 99.9%)	98.7% (98.3%; 99.1%)	98.0% (97.5%; 98.6%)	96.9% (96.0%; 97.9%)
	<b>50-64</b>	4,034	99.6% (99.3%; 99.8%)	98.5% (97.9%; 99.0%)	98.0% (97.3%; 98.8%)	97.7% (96.2%; 99.2%)
	<b>65+</b>	4,535	97.9% (97.2%; 98.7%)	95.5% (94.1%; 97.0%)	94.7% (92.5%; 96.9%)	101.2% (94.5%; 108.3%)
Wallonia	<b>All ages</b>	5,304	98.5% (98.1%; 99.0%)	96.0% (95.2%; 96.9%)	94.2% (92.9%; 95.6%)	95.6% (92.3%; 99.1%)
	<b>15-49</b>	1,941	99.7% (99.4%; 100.0%)	98.8% (98.3%; 99.4%)	98.4% (97.7%; 99.1%)	98.2% (97.2%; 99.3%)
	<b>50-64</b>	1,531	98.7% (98.0%; 99.3%)	97.5% (96.5%; 98.5%)	96.4% (95.1%; 97.7%)	94.8% (92.3%; 97.3%)
	<b>65+</b>	1,842	97.3% (96.0%; 98.5%)	91.9% (89.6%; 94.3%)	87.8% (84.2%; 91.7%)	93.8% (83.7%; 105.1%)

## 4.2. Melanoma survival: by tumour stage

### 4.2.1. Melanoma survival by clinical stage (cStage) and sex: number at risk and net survival probabilities, 2013-2022

Net Survival Probability, 2013-2022							
cStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
<b>Total</b>	43,107	97.8% (97.6%; 98.0%)	96.1% (95.8%; 96.4%)	94.9% (94.5%; 95.2%)	94.0% (93.6%; 94.4%)	93.6% (93.1%; 94.1%)	93.7% (92.3%; 95.1%)
<b>Males</b>							
<b>Total</b>	18,407	96.9% (96.6%; 97.3%)	94.5% (94.0%; 95.0%)	93.0% (92.4%; 93.6%)	92.2% (91.5%; 92.9%)	91.8% (91.0%; 92.7%)	91.8% (89.4%; 94.3%)
<b>I</b>	12,520	100.8% (100.6%; 101.0%)	101.2% (100.8%; 101.6%)	101.8% (101.3%; 102.3%)	102.6% (102.0%; 103.2%)	103.2% (102.4%; 104.0%)	107.0% (104.6%; 109.3%)
<b>II</b>	3,724	95.8% (94.9%; 96.8%)	87.6% (86.2%; 89.1%)	80.7% (78.9%; 82.6%)	76.2% (74.1%; 78.4%)	72.9% (70.5%; 75.4%)	64.5% (57.3%; 72.6%)
<b>III</b>	302	83.9% (79.5%; 88.6%)	72.0% (66.5%; 77.9%)	66.9% (60.9%; 73.4%)	59.0% (52.4%; 66.4%)	56.3% (49.1%; 64.7%)	48.6% (38.4%; 61.4%)
<b>IV</b>	360	53.4% (48.2%; 59.0%)	39.4% (34.3%; 45.2%)	30.3% (25.4%; 36.2%)	26.7% (21.8%; 32.7%)	24.2% (19.2%; 30.5%)	11.0% (5.5%; 22.0%)
<b>X/NA</b>	1,700	81.7% (79.7%; 83.7%)	75.4% (73.1%; 77.8%)	72.8% (70.2%; 75.4%)	70.5% (67.8%; 73.4%)	70.3% (67.3%; 73.3%)	69.1% (63.0%; 75.8%)
<b>Females</b>							
<b>Total</b>	24,700	98.5% (98.3%; 98.8%)	97.3% (96.9%; 97.6%)	96.3% (95.8%; 96.7%)	95.3% (94.8%; 95.9%)	95.0% (94.4%; 95.6%)	95.1% (93.5%; 96.8%)
<b>I</b>	18,282	100.5% (100.4%; 100.7%)	101.0% (100.7%; 101.2%)	101.2% (100.9%; 101.5%)	101.3% (100.9%; 101.7%)	101.6% (101.1%; 102.0%)	104.2% (102.7%; 105.8%)
<b>II</b>	4,027	97.0% (96.2%; 97.8%)	91.0% (89.7%; 92.4%)	86.2% (84.5%; 87.8%)	81.4% (79.4%; 83.4%)	78.9% (76.7%; 81.3%)	69.7% (65.3%; 74.5%)
<b>III</b>	298	89.2% (85.4%; 93.3%)	75.6% (70.3%; 81.2%)	67.4% (61.5%; 73.9%)	64.4% (57.9%; 71.5%)	61.3% (54.6%; 68.9%)	53.7% (44.1%; 65.4%)
<b>IV</b>	242	64.7% (58.6%; 71.3%)	47.9% (41.6%; 55.2%)	39.9% (33.5%; 47.5%)	32.4% (25.9%; 40.4%)	30.2% (23.8%; 38.4%)	24.6% (17.6%; 34.5%)
<b>X/NA</b>	2,032	88.6% (87.1%; 90.1%)	85.0% (83.2%; 86.9%)	82.3% (80.3%; 84.4%)	81.0% (78.8%; 83.3%)	80.4% (77.9%; 82.9%)	80.3% (74.2%; 86.9%)

4.2.2. Melanoma survival by pathological stage (pStage) and sex: number at risk and net survival probabilities, 2013-2022

Net Survival Probability, 2013-2022							
pStage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
<b>Total</b>	43,107	97.8% (97.6%; 98.0%)	96.1% (95.8%; 96.4%)	94.9% (94.5%; 95.2%)	94.0% (93.6%; 94.4%)	93.6% (93.1%; 94.1%)	93.7% (92.3%; 95.1%)
<b>Males</b>							
<b>Total</b>	18,407	96.9% (96.6%; 97.3%)	94.5% (94.0%; 95.0%)	93.0% (92.4%; 93.6%)	92.2% (91.5%; 92.9%)	91.8% (91.0%; 92.7%)	91.8% (89.4%; 94.3%)
<b>I</b>	12,256	100.8% (100.6%; 101.1%)	101.3% (100.9%; 101.6%)	101.9% (101.4%; 102.4%)	102.7% (102.1%; 103.4%)	103.4% (102.6%; 104.2%)	107.3% (104.9%; 109.7%)
<b>II</b>	3,073	94.9% (93.8%; 96.0%)	88.2% (86.6%; 89.9%)	82.2% (80.1%; 84.2%)	78.3% (75.9%; 80.7%)	74.8% (72.1%; 77.7%)	66.8% (58.2%; 76.5%)
<b>III</b>	1,319	92.9% (91.3%; 94.6%)	82.1% (79.7%; 84.5%)	74.1% (71.3%; 77.0%)	67.6% (64.6%; 70.9%)	65.7% (62.4%; 69.2%)	57.9% (53.1%; 63.0%)
<b>IV</b>	217	61.8% (55.4%; 69.0%)	42.2% (35.7%; 49.8%)	35.8% (29.5%; 43.6%)	34.1% (27.7%; 42.1%)	32.2% (25.7%; 40.4%)	25.0% (17.0%; 36.7%)
<b>X/NA</b>	1,760	80.1% (78.1%; 82.2%)	73.6% (71.3%; 76.0%)	70.8% (68.3%; 73.4%)	68.4% (65.7%; 71.3%)	67.9% (64.9%; 70.9%)	66.0% (60.0%; 72.6%)
<b>Females</b>							
<b>Total</b>	24,700	98.5% (98.3%; 98.8%)	97.3% (96.9%; 97.6%)	96.3% (95.8%; 96.7%)	95.3% (94.8%; 95.9%)	95.0% (94.4%; 95.6%)	95.1% (93.5%; 96.8%)
<b>I</b>	17,986	100.5% (100.4%; 100.7%)	101.0% (100.8%; 101.2%)	101.3% (101.0%; 101.6%)	101.4% (101.1%; 101.8%)	101.8% (101.3%; 102.3%)	104.7% (103.1%; 106.2%)
<b>II</b>	3,436	96.8% (95.9%; 97.8%)	90.8% (89.3%; 92.3%)	86.0% (84.2%; 87.9%)	81.8% (79.6%; 84.1%)	79.3% (76.8%; 81.9%)	70.1% (65.1%; 75.5%)
<b>III</b>	1,244	95.6% (94.2%; 97.0%)	88.3% (86.2%; 90.4%)	82.6% (80.1%; 85.2%)	76.8% (73.9%; 79.9%)	73.8% (70.7%; 77.1%)	65.2% (60.6%; 70.3%)
<b>IV</b>	150	72.0% (64.9%; 79.9%)	60.1% (52.2%; 69.1%)	53.6% (45.4%; 63.3%)	43.2% (34.3%; 54.3%)	40.4% (31.5%; 51.8%)	35.7% (25.1%; 50.8%)
<b>X/NA</b>	2,075	87.5% (86.0%; 89.1%)	83.5% (81.6%; 85.4%)	80.7% (78.7%; 82.9%)	79.4% (77.2%; 81.7%)	78.8% (76.3%; 81.3%)	78.7% (72.7%; 85.2%)

4.2.3. Melanoma survival by stage and sex: number at risk and net survival probabilities, 2013-2022

Net Survival Probability, 2013-2022							
Stage	N at risk	1-y (95%CI)	2-y (95%CI)	3-y (95%CI)	4-y (95%CI)	5-y (95%CI)	10-y (95%CI)
<b>Total</b>	43,107	97.8% (97.6%; 98.0%)	96.1% (95.8%; 96.4%)	94.9% (94.5%; 95.2%)	94.0% (93.6%; 94.4%)	93.6% (93.1%; 94.1%)	93.7% (92.3%; 95.1%)
<b>Males</b>							
<b>Total</b>	18,407	96.9% (96.6%; 97.3%)	94.5% (94.0%; 95.0%)	93.0% (92.4%; 93.6%)	92.2% (91.5%; 92.9%)	91.8% (91.0%; 92.7%)	91.8% (89.4%; 94.3%)
<b>I</b>	12,239	100.9% (100.6%; 101.1%)	101.3% (100.9%; 101.7%)	102.0% (101.5%; 102.5%)	102.8% (102.2%; 103.5%)	103.5% (102.7%; 104.3%)	107.5% (105.1%; 109.9%)
<b>II</b>	2,990	96.4% (95.3%; 97.4%)	89.9% (88.3%; 91.5%)	83.8% (81.8%; 85.9%)	79.9% (77.5%; 82.4%)	76.5% (73.7%; 79.4%)	68.4% (59.7%; 78.4%)
<b>III</b>	1,295	93.4% (91.8%; 95.1%)	82.5% (80.1%; 84.9%)	75.1% (72.3%; 78.0%)	68.7% (65.7%; 72.0%)	66.6% (63.3%; 70.2%)	58.5% (53.6%; 63.7%)
<b>IV</b>	456	57.9% (53.3%; 62.9%)	41.7% (37.1%; 46.9%)	32.9% (28.4%; 38.1%)	30.1% (25.5%; 35.5%)	27.4% (22.7%; 32.9%)	17.1% (11.4%; 25.8%)
<b>X/NA</b>	1,646	81.7% (79.7%; 83.8%)	75.7% (73.3%; 78.1%)	73.1% (70.5%; 75.8%)	70.8% (68.0%; 73.7%)	70.5% (67.5%; 73.6%)	69.2% (62.9%; 76.0%)
<b>Females</b>							
<b>Total</b>	24,700	98.5% (98.3%; 98.8%)	97.3% (96.9%; 97.6%)	96.3% (95.8%; 96.7%)	95.3% (94.8%; 95.9%)	95.0% (94.4%; 95.6%)	95.1% (93.5%; 96.8%)
<b>I</b>	17,975	100.6% (100.4%; 100.7%)	101.0% (100.8%; 101.2%)	101.3% (101.0%; 101.6%)	101.5% (101.1%; 101.9%)	101.8% (101.3%; 102.3%)	104.7% (103.1%; 106.3%)
<b>II</b>	3,379	97.3% (96.4%; 98.2%)	91.6% (90.2%; 93.1%)	86.9% (85.1%; 88.8%)	82.9% (80.7%; 85.1%)	80.4% (77.8%; 83.0%)	71.1% (66.1%; 76.5%)
<b>III</b>	1,241	95.6% (94.3%; 97.0%)	88.5% (86.4%; 90.6%)	83.0% (80.5%; 85.6%)	77.5% (74.6%; 80.5%)	74.3% (71.1%; 77.6%)	65.6% (60.9%; 70.7%)
<b>IV</b>	308	67.5% (62.2%; 73.3%)	51.8% (46.1%; 58.2%)	43.2% (37.4%; 49.9%)	34.5% (28.4%; 41.8%)	32.5% (26.4%; 39.9%)	28.0% (21.0%; 37.2%)
<b>X/NA</b>	1,989	88.7% (87.2%; 90.3%)	85.1% (83.3%; 87.0%)	82.6% (80.5%; 84.7%)	81.3% (79.0%; 83.6%)	80.7% (78.2%; 83.2%)	80.8% (74.7%; 87.5%)



## 5. CANCER SURVIVAL TRENDS



### 5.1. Melanoma survival trends: by tumour stage

#### 5.1.1. Melanoma survival trends by stage and sex: number at risk and net survival probabilities, 2008-2022

Period	Stage	Males				Females			
		N at risk	Net Survival Probability			N at risk	Net Survival Probability		
			1-y (95%CI)	3-y (95%CI)	5-y (95%CI)		1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
2008-2012	All	4,313	94.9% (94.1%; 95.7%)	88.3% (87.0%; 89.7%)	86.0% (84.4%; 87.6%)	6,183	97.7% (97.2%; 98.2%)	94.2% (93.4%; 95.1%)	92.5% (91.4%; 93.6%)
	I	2,280	100.3% (99.7%; 100.8%)	100.4% (99.2%; 101.5%)	100.8% (99.1%; 102.4%)	3,663	100.4% (100.1%; 100.7%)	100.6% (99.9%; 101.2%)	100.4% (99.5%; 101.4%)
	II	711	95.5% (93.3%; 97.7%)	78.1% (74.1%; 82.3%)	69.6% (64.7%; 74.7%)	832	97.3% (95.6%; 99.1%)	82.5% (79.0%; 86.2%)	76.3% (71.8%; 81.0%)
	III	279	87.4% (83.2%; 91.8%)	63.6% (57.6%; 70.1%)	54.0% (47.7%; 61.2%)	288	93.6% (90.5%; 96.8%)	81.0% (76.0%; 86.2%)	70.9% (65.1%; 77.2%)
	IV	133	51.5% (43.4%; 61.0%)	23.7% (17.1%; 32.9%)	19.2% (13.0%; 28.3%)	97	63.7% (54.5%; 74.4%)	46.0% (36.5%; 58.0%)	35.0% (25.8%; 47.5%)
	X/NA	941	89.5% (87.3%; 91.7%)	82.9% (79.9%; 86.1%)	80.8% (77.2%; 84.6%)	1,329	93.9% (92.4%; 95.4%)	90.2% (88.0%; 92.4%)	89.2% (86.5%; 92.0%)
2013-2017	All	6,103	96.5% (95.9%; 97.2%)	92.8% (91.7%; 93.8%)	92.0% (90.6%; 93.3%)	8,505	98.6% (98.3%; 99.0%)	96.5% (95.8%; 97.2%)	95.2% (94.3%; 96.2%)
	I	4,145	100.9% (100.5%; 101.3%)	101.9% (101.1%; 102.7%)	103.9% (102.7%; 105.1%)	6,384	100.6% (100.4%; 100.8%)	101.2% (100.7%; 101.6%)	101.8% (101.1%; 102.5%)
	II	1,031	94.8% (92.9%; 96.8%)	82.6% (79.4%; 86.1%)	74.7% (70.4%; 79.2%)	1,234	96.1% (94.4%; 97.7%)	87.7% (84.8%; 90.7%)	80.7% (76.8%; 84.9%)
	III	445	94.2% (91.6%; 96.8%)	76.4% (72.0%; 81.1%)	70.9% (65.8%; 76.4%)	444	95.6% (93.3%; 97.9%)	81.8% (77.7%; 86.1%)	72.7% (67.8%; 77.9%)
	IV	145	57.4% (49.6%; 66.5%)	34.1% (26.7%; 43.5%)	29.7% (22.3%; 39.7%)	91	72.5% (63.5%; 82.8%)	42.1% (32.4%; 54.7%)	36.0% (26.2%; 49.5%)
	X/NA	380	71.2% (66.6%; 76.2%)	59.6% (54.1%; 65.5%)	55.8% (49.8%; 62.7%)	383	84.4% (80.5%; 88.5%)	75.4% (70.3%; 80.8%)	71.5% (65.6%; 77.8%)
2018-2022	All	8,205	98.3% (97.8%; 98.8%)	95.8% (94.9%; 96.8%)	95.3% (93.8%; 96.9%)	10,306	99.0% (98.6%; 99.3%)	97.5% (96.8%; 98.2%)	96.8% (95.7%; 97.9%)
	I	5,941	101.1% (100.7%; 101.4%)	102.7% (101.9%; 103.5%)	104.3% (102.8%; 105.8%)	8,121	100.7% (100.5%; 100.8%)	101.9% (101.4%; 102.3%)	102.6% (101.7%; 103.5%)
	II	1,257	97.8% (96.3%; 99.4%)	87.9% (84.6%; 91.4%)	83.8% (78.6%; 89.4%)	1,322	98.4% (97.0%; 99.9%)	89.0% (85.9%; 92.2%)	83.5% (78.6%; 88.7%)

Period	Stage	Males				Females			
		Net Survival Probability				Net Survival Probability			
		N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)	N at risk	1-y (95%CI)	3-y (95%CI)	5-y (95%CI)
	III	573	95.8% (93.7%; 98.0%)	80.3% (76.1%; 84.7%)	68.1% (62.1%; 74.6%)	510	96.9% (94.9%; 98.9%)	85.6% (81.5%; 89.9%)	80.9% (75.6%; 86.5%)
	IV	178	63.2% (56.1%; 71.2%)	39.3% (31.7%; 48.8%)	29.2% (19.6%; 43.5%)	121	66.3% (58.0%; 75.9%)	41.9% (32.5%; 53.9%)	25.2% (14.9%; 42.4%)
	X/NA	325	71.7% (66.6%; 77.2%)	59.6% (53.1%; 66.9%)	56.7% (48.5%; 66.3%)	278	69.7% (64.3%; 75.7%)	54.6% (48.1%; 62.0%)	49.5% (41.9%; 58.5%)

## 6. CANCER MORTALITY



### 6.1. Melanoma mortality: by region

6.1.1. *Melanoma mortality\* by region and sex: number of cancer deaths, age-specific, crude and age-standardised mortality rates, 2021*

Region	N [CR]																				All ages	ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-			
Males																							
<b>Belgium</b>	0	0	0	0	0	1	1	2	3	4	11	16	10	20	27	24	21	23	9	2	174	3.4	
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[0.3]	[0.5]	[0.8]	[1.1]	[2.8]	[4.0]	[2.8]	[6.5]	[10.2]	[13.8]	[16.1]	[29.6]	[32.1]	[36.7]	[3.1]	(2.9; 3.9)	
Brussels	0	0	0	0	0	0	0	0	0	0	1	0	2	1	1	2	2	0	1	1	0	11	3.0
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[2.3]	[0.0]	[5.9]	[3.7]	[4.8]	[12.0]	[17.4]	[0.0]	[19.8]	[46.0]	[0.0]	[1.8]	(1.2; 4.8)
Flanders	0	0	0	0	0	1	1	2	2	3	9	8	8	17	15	15	17	17	4	2	121	3.7	
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[0.5]	[1.0]	[0.9]	[1.4]	[3.8]	[3.3]	[3.6]	[9.1]	[9.3]	[13.1]	[19.7]	[32.9]	[21.8]	[55.9]	[3.7]	(3.1; 4.4)	
Wallonia	0	0	0	0	0	0	0	0	1	0	2	6	1	2	10	7	4	5	4	0	42	2.9	
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[0.0]	[1.6]	[4.8]	[0.9]	[2.0]	[11.6]	[14.4]	[11.1]	[23.9]	[52.8]	[0.0]	[2.4]	(2.0; 3.8)	
Females																							
<b>Belgium</b>	0	0	0	0	0	0	1	4	5	7	10	4	12	20	16	28	24	18	11	4	164	2.6	
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.3]	[1.1]	[1.3]	[1.9]	[2.6]	[1.0]	[3.2]	[6.1]	[5.4]	[13.1]	[13.0]	[13.3]	[16.6]	[20.8]	[2.8]	(2.2; 3.0)	
Brussels	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	2	2	0	0	2	0	9	1.9
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[3.0]	[3.4]	[4.1]	[9.3]	[12.3]	[0.0]	[0.0]	[34.8]	[0.0]	[1.4]	(0.6; 3.1)

Region	N [CR]																				ESR2013 (95%CI)	
	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80-	85-	90-	95-		All ages
Flanders	0	0	0	0	0	0	1	3	2	6	5	3	6	14	9	19	16	15	6	3	108	2.8
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.5]	[1.4]	[0.9]	[2.9]	[2.2]	[1.3]	[2.7]	[7.3]	[5.2]	[14.3]	[13.8]	[17.6]	[15.0]	[26.7]	[3.2]	(2.3; 3.3)
Wallonia	0	0	0	0	0	0	0	1	3	1	5	0	5	5	5	7	8	3	3	1	47	2.4
	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.0]	[0.9]	[2.6]	[0.8]	[4.0]	[0.0]	[4.1]	[4.6]	[5.0]	[11.0]	[14.5]	[7.5]	[14.7]	[16.6]	[2.5]	(1.7; 3.1)

## 7. CANCER MORTALITY TRENDS



### 7.1. Melanoma mortality trends: by region

7.1.1. Melanoma mortality\* trends in males, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	AAPC, % (95%CI)	Period	
Belgium	<b>N</b>	130	149	145	151	167	163	167	179	155	196	171	169	184	175	189	153	173	174			
	<b>CR</b>	2.6	2.9	2.8	2.9	3.2	3.1	3.1	3.3	2.9	3.6	3.1	3.1	3.3	3.1	3.4	2.7	3.1	3.1			
	<b>ESR2013</b>		3.2	3.7	3.4	3.4	4.0	3.7	3.9	4.1	3.5	4.3	3.6	3.5	3.8	3.5	3.8	3.1	3.3	3.4	-0.3 (-0.9; 0.4)	2004-2021
																					1.7 (0.2; 3.1)	2004-2013
																					-2.4 (-3.9; -0.8)	2014-2021
Brussels	<b>N</b>	9	10	11	13	10	7	12	11	11	7	11	8	11	13	13	11	9	11			
	<b>CR</b>	1.9	2.1	2.2	2.6	2.0	1.4	2.3	2.0	2.0	1.2	1.9	1.4	1.9	2.2	2.2	1.9	1.5	1.8			
	<b>ESR2013</b>	2.2	2.6	3.3	3.6	2.4	1.7	3.3	3.4	3.3	2.0	3.0	2.0	3.5	3.5	3.6	3.1	2.4	3.0	0.9 (-1.4; 3.2)	2004-2021	
Flanders	<b>N</b>	72	101	104	86	112	108	111	118	100	132	107	119	117	119	128	99	103	121			
	<b>CR</b>	2.4	3.4	3.5	2.9	3.7	3.5	3.6	3.8	3.2	4.2	3.4	3.7	3.7	3.7	3.9	3.0	3.1	3.7			
	<b>ESR2013</b>		3.0	4.1	4.0	3.2	4.3	4.2	4.2	4.3	3.6	4.7	3.6	4.0	3.8	3.8	4.1	3.2	3.2	3.7	-0.3 (-1.4; 0.8)	2004-2021
																				2.0 (-0.2; 4.4)	2004-2013	
																					-2.8 (-5.3; -0.3)	2014-2021
Wallonia	<b>N</b>	49	38	30	52	45	48	44	50	44	57	53	42	56	43	48	43	61	42			
	<b>CR</b>	3.0	2.3	1.8	3.1	2.7	2.8	2.6	2.9	2.6	3.3	3.0	2.4	3.2	2.4	2.7	2.4	3.4	2.4			

Region	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	AAPC, % (95%CI)	Period
<b>ESR2013</b>	3.9	3.3	2.5	3.8	3.7	3.4	3.5	3.8	3.4	4.2	3.7	3.0	3.8	2.9	3.2	2.8	4.0	2.9	-0.4 (-1.8; 1.0)	2004-2021

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

7.1.2. Melanoma mortality\* trends in females, by region: number of cancer deaths, crude and age-standardised mortality rates, including average annual percentage change, 2004-2021

Region		2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	AAPC, % (95%CI)	Period
Belgium	<b>N</b>	146	131	122	151	150	154	149	173	136	185	185	157	154	150	166	152	149	164		
	<b>CR</b>	2.7	2.5	2.3	2.8	2.8	2.8	2.7	3.1	2.4	3.3	3.3	2.8	2.7	2.6	2.9	2.6	2.6	2.8		
	<b>ESR2013</b>	2.7	2.5	2.3	2.8	2.7	2.7	2.6	3.0	2.3	3.2	3.1	2.6	2.5	2.4	2.6	2.4	2.3	2.6	-0.4 (-1.4; 0.6)	2004-2021
Brussels	<b>N</b>	18	8	12	12	11	11	11	15	13	18	16	10	10	11	17	8	7	9		
	<b>CR</b>	3.5	1.5	2.3	2.2	2.0	2.0	2.0	2.6	2.2	3.0	2.7	1.7	1.6	1.8	2.8	1.3	1.1	1.4		
	<b>ESR2013</b>	3.7	1.8	2.6	2.7	2.2	2.3	2.1	3.1	2.4	3.3	3.0	1.8	1.9	2.0	3.0	1.3	1.4	1.9	-2.6 (-5.0; -0.2)	2004-2021
Flanders	<b>N</b>	95	77	71	102	95	108	89	110	86	121	128	103	101	105	99	116	106	108		
	<b>CR</b>	3.1	2.5	2.3	3.3	3.0	3.4	2.8	3.4	2.7	3.7	3.9	3.2	3.1	3.2	3.0	3.5	3.2	3.2		
	<b>ESR2013</b>	3.1	2.6	2.3	3.2	2.9	3.2	2.7	3.3	2.4	3.5	3.6	2.9	2.8	2.9	2.6	3.1	2.7	2.8	0.0 (-1.2; 1.3)	2004-2021
Wallonia	<b>N</b>	33	46	39	37	44	35	49	48	37	46	41	44	43	34	50	28	36	47		
	<b>CR</b>	1.9	2.6	2.2	2.1	2.5	2.0	2.7	2.7	2.0	2.5	2.2	2.4	2.3	1.8	2.7	1.5	1.9	2.5		
	<b>ESR2013</b>	1.9	2.7	2.3	2.1	2.5	2.0	2.6	2.6	2.0	2.4	2.0	2.3	2.2	1.8	2.4	1.4	1.9	2.4	-1.0 (-2.6; 0.6)	2004-2021

Note: In case a change in trend is detected, an estimated APC per time segment is given as well as Average Annual Percentage Change (AAPC) for the full incidence period.

\*Mortality statistics in Belgium are collected and managed by the three Regions (Flemish Region: Departement Zorg; Brussels-Capital Region: Observatorium voor Gezondheid en Welzijn van Brussel-Hoofdstad/ l'Observatoire de la Santé et du Social de Bruxelles-Capitale; Walloon Region: Agence Wallonne de la Santé, de la Protection sociale, du Handicap et des Familles (AVIQ)). The Directorate General Statistics Belgium is responsible for collecting and merging the data coming from the regional agencies. Mortality data used in this cancer fact sheet are collected from the Directorate General Statistics Belgium and encompasses the period 2004-2021.

Recommended reference: Cancer Fact Sheets 2022, Belgian Cancer Registry (BCR), 2024